Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologyHealth Net Selexipag (Uptravi) Coverage Update | O…
    Ask Trek AI about this page
    ModifiedHealth NetPolicy CP.PHAR.196

    Selexipag (Uptravi) — Coverage Criteria

    Customize your policy alerts

    Sign up for Health Net Policy CP.PHAR.196 alerts

    Get alerted when Policy CP.PHAR.196 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for selexipag (Uptravi) for treatment of pulmonary arterial hypertension (PAH) across Health Net lines of business including Commercial, HIM, and Medicaid.

    Policy Summary
    PayerHealth Net
    PolicySelexipag (Uptravi) — Coverage Criteria
    Policy CodePolicy CP.PHAR.196
    Change TypeAdded IV formulationclarified dosing with CYP2C8 inducersrevised commercial duration
    Effective Date
    Next Review DateFeb 25, 2025
    Key ActionSubmit documentation (chart notes, labs, titration plan) and specify dose and formulation when requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Added IV Uptravi 1800 mcg/10 mL formulation and criteria for use per prescribing information.

    Clarified that concomitant administration with CYP2C8 inducers may require higher doses.

    Revised approval duration for Commercial line of business to 12 months or duration of request, whichever is less.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    PAHIndication
    Commercial, HIM, MedicaidLines of business
    3200 mcg/dayOral max
    3600 mcg/dayIV max
    Oral & IVFormulations
    Commercial 12 moApproval duration

    Coverage Criteria for Selexipag (Uptravi)

    inv-01: Initial Therapy — Covered when ALL of the following are met:

    Covered when ALL of the following are met:

    Initial approval requirements: 1. Diagnosis of pulmonary arterial hypertension (PAH, WHO Group 1). 2. Prescribed by or in consultation with a cardiologist or pulmonologist. 3. Inadequate response to or contraindication to acute vasodilator testing. 4. Failure of a calcium channel blocker unless there is a contraindication or clinically significant adverse effects. 5. Requested dose does not exceed the maximums specified for the formulation (oral or IV); note that concomitant administration with CYP2C8 inducers (e.g., rifampin) may require higher doses. 6. If the request is for intravenous Uptravi, the member is temporarily unable to take oral therapy. 7. If the request is for titration, the provider must submit a titration plan.

    inv-02: Continuation Therapy — Covered when ALL of the following are met:

    Covered when ALL of the following are met:

    Continuation requirements: 1. Member is currently receiving medication via the health plan benefit or previously met initial approval criteria (including continuity-of-care provisions where applicable). 2. Member is responding positively to therapy. 3. If the request is for a dose increase, the new dose does not exceed the maximums specified for the formulation; note that concomitant administration with CYP2C8 inducers (e.g., rifampin) may require higher doses. 4. If the request is for intravenous Uptravi, the member is temporarily unable to take oral therapy. 5. If the request is for titration, the provider must submit a titration plan.

    inv-03: Initial and dosing requirements — Coverage aligned to Uptravi prescribing information and policy updates

    Coverage aligned to Uptravi prescribing information and policy updates

    Formulation availability: Provider documents use of available formulations: tablets (200–1600 mcg strengths) or IV single‑dose vial 1800 mcg/10 mL.

    Formulations listed in Product Availability section

    Requests for use of selexipag (Uptravi) for non‑FDA approved indications that are not specifically addressed by this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety consistent with the applicable off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid), or other evidence of coverage documents.

    Appendix B was updated to remove commercially unavailable branded products per Clinical Pharmacology review; these removed brands are no longer considered as therapeutic alternatives for coverage decisions and have been excluded from the policy appendices.

    Use of selexipag for diagnoses or indications that are not listed in this policy is considered not authorized unless the provider supplies adequate off‑label documentation in accordance with the referenced off‑label use policies (see CP.CPA.09, HIM.PA.154, CP.PMN.53 or evidence of coverage documents).

    There are no additional explicit not medically necessary conditions specified beyond the standard exclusions and off‑label limitations already described in this policy and its appendices; policy updates have focused on formulation availability and dosing clarifications rather than adding new NMN statements.

    Coding, Dosing, and Formulations

    NDC / BillingNDC
    NDCNot listed in this document
    Product NDC / formulationsNDC
    NDCIV single-dose vial 1800 mcg/10 mL; multiple tablet strengths 200 mcg–1600 mcg
    Maximum daily dose — Oral and Intravenous maximums
    Oral maximum3,200 mcg per day (tablets)
    Intravenous maximum3,600 mcg per day (IV injection)
    CYP2C8 inducers noteConcomitant administration with CYP2C8 inducers (e.g., rifampin) may require higher doses — ensure documentation of dose adjustments.
    Oral dosing titration — Start and titration schedule
    Starting dose200 mcg orally twice daily (PO BID)
    Titration scheduleIncrease at weekly intervals to the highest tolerated dose

    Prior Authorization, Documentation, and Prescribing Requirements

    Prior Authorization

    Obtain prior authorization and meet approval durations

    Prior authorization is required and will only be granted when the member meets the policy's initial or continuation criteria; approvals are issued for specified durations by line of business (Medicaid/HIM initial 6 months; Commercial initial 12 months or duration of request, whichever is less).

    Prior Authorization

    Specify dose, formulation, and clinical rationale

    When requesting prior authorization, include the specific dose, formulation (oral tablet strengths or IV single‑dose vial 1800 mcg/10 mL), and clinical rationale consistent with the Uptravi prescribing information.

    Step Therapy

    Confirm failure of calcium channel blocker prior to approval

    Definitions and Drug Class

    PAH (WHO Group 1) — Indication definition
    DefinitionPulmonary arterial hypertension (PAH) — WHO Group 1; selexipag is indicated to delay disease progression and reduce risk of hospitalization for PAH.
    Typical patient populationEffectiveness demonstrated in patients with WHO Functional Class II–III symptoms, including idiopathic/heritable, connective tissue disease–associated, and repaired congenital heart disease subgroups.
    Prescriber requirementTherapy should be prescribed by or in consultation with a cardiologist or pulmonologist per initial criteria.
    Prostacyclin pathway agent / IP receptor agonist — Drug class/mechanism
    Class / mechanismNon‑prostanoid prostacyclin (IP) receptor agonist — reduces pulmonary arterial pressure through vasodilation.
    Pathway

    Background

    Selexipag (Uptravi) is a prostacyclin pathway agent — a non‑prostanoid prostacyclin (IP) receptor agonist — developed to reduce pulmonary arterial pressure through vasodilation in patients with pulmonary arterial hypertension (WHO Group 1). Clinical intent of therapy is to delay disease progression and reduce the risk of hospitalization; recent policy updates added an IV formulation (single‑dose vial 1800 mcg/10 mL) and clarified dosing considerations when coadministered with CYP2C8 inducers.

    Policy Revision History and Material Changes

    2024-02 (P&T Approval Date: 02.24)material_updateLatest

    1Q 2024 annual review added IV Uptravi 1800 mcg/10 mL formulation and incorporated criteria for IV use per prescribing information; clarified dosing adjustments when coadministered with CYP2C8 inducers.

    2022-11 (P&T Approval Date: 11.22)administrative_revision

    Revised approval duration for Commercial line of business to 12 months or duration of request, whichever is less; template changes applied to other diagnoses/continued therapy sections.

    2021-02 (P&T Approval Date: 02.21)
    Policy Summary
    PayerHealth Net
    PolicySelexipag (Uptravi) — Coverage Criteria
    Policy CodePolicy CP.PHAR.196
    Change TypeAdded IV formulationclarified dosing with CYP2C8 inducersrevised commercial duration
    Effective Date
    Next Review DateFeb 25, 2025
    Key ActionSubmit documentation (chart notes, labs, titration plan) and specify dose and formulation when requesting prior authorization.
    SourceLink
    On This Page
    Coverage Criteria for Selexipag (Uptravi)Coding, Dosing, and FormulationsPrior Authorization, Documentation, and Prescribing RequirementsDefinitions and Drug ClassBackgroundPolicy Revision History and Material Changes
    Target/tolerated rangeTitration up to 1,600 mcg twice daily (1600 mcg BID)
    Maximum doses — Oral max 3200 mcg/day; IV max 3600 mcg/day
    Maximum oral daily dose3,200 mcg/day (tablets)
    Maximum IV daily dose3,600 mcg/day (injection)
    Dose correspondenceIV dosing should correspond to the patient’s current oral dose when IV therapy is indicated.

    Document that the member has had failure of a calcium channel blocker unless there is a documented contraindication or clinically significant adverse effect to calcium channel blockers; therapeutic alternatives are listed in Appendix B.

    • Failure of a calcium channel blocker is required unless contraindicated or intolerant
    • Appendix B lists therapeutic alternatives (e.g., nifedipine, diltiazem, amlodipine)
    Step Therapy

    No explicit step sequence beyond CCB failure

    No additional step therapy sequencing is specified by this policy beyond the requirement to document failure of a calcium channel blocker when applicable.

    Documentation Required

    Provide clinical documentation and titration plan as required

    Submit supporting clinical documentation such as office chart notes, titration plans (if request is for titration), and relevant lab or clinical data demonstrating the diagnosis of PAH and that approval criteria are met.

    • Provide a titration plan if the request is for titration
    • For IV requests, document temporary inability to take oral therapy
    Documentation Required

    Align documentation with Uptravi prescribing information

    Ensure submitted documentation aligns with the Uptravi prescribing information for formulation and dosing—specifically IV Uptravi 1800 mcg/10 mL when used, and note that concomitant administration with CYP2C8 inducers may require higher doses.

    Denial Risk

    Off‑label indication requests must meet off‑label policies

    Requests for non‑FDA approved (off‑label) indications not addressed in this policy may be denied unless adequate off‑label use documentation is provided per the referenced off‑label use policies.

    • Follow off‑label documentation requirements in CP.CPA.09 (Commercial), HIM.PA.154 (HIM), or CP.PMN.53 (Medicaid) as applicable
    Denial Risk

    Avoid documentation/dosing mismatches with IV formulation and CYP2C8 guidance

    Coverage and authorization may be affected or denied if submitted documentation does not reflect the updated IV formulation criteria (IV 1800 mcg/10 mL) or dosing adjustments when selexipag is coadministered with CYP2C8 inducers.

    • Ensure IV requests document use of the single‑dose 1800 mcg/10 mL vial and rationale for IV use (temporary inability to take oral therapy)
    • Document consideration of higher doses when coadministered with CYP2C8 inducers (e.g., rifampin)
    Acts on the prostacyclin pathway to produce vasodilatory effects in pulmonary vasculature.
    Related therapeutic classesRelated PAH classes include endothelin receptor antagonists, phosphodiesterase‑5 inhibitors, and soluble guanylate cyclase stimulators.
    Selexipag / Uptravi — Agent description and related agents
    AgentSelexipag (Uptravi) — oral tablet formulation; non‑prostanoid IP receptor agonist indicated for PAH.
    Formulations availableTablets (200–1600 mcg strengths) and single‑dose IV vial (1800 mcg/10 mL)
    Clinical effectReduces pulmonary arterial pressure through vasodilation and delays disease progression, reducing risk of hospitalization in PAH.
    Related agentsOther prostacyclin pathway agents include treprostinil (oral/IV/inhaled), iloprost (inhaled), and epoprostenol (IV).
    administrative_review

    1Q 2021 annual review: references revised (HIMPHAR.21 updated to HIM.PA.154) and references reviewed and updated.

    2022-02 (P&T Approval Date: 02.22)annual_review

    1Q 2022 annual review: no significant changes; references reviewed and updated.

    2023-02 (P&T Approval Date: 02.23)annual_review

    1Q 2023 annual review: no significant changes; references reviewed and updated.